Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.97
+0.27002.78%
Volume:731.77K
Turnover:7.20M
Market Cap:2.50B
PE:8.24
High:9.98
Open:9.83
Low:9.68
Close:9.70
52wk High:11.31
52wk Low:6.00
Shares:250.80M
Float Shares:218.00M
Volume Ratio:0.93
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:587.33%
ROA:43.21%
PB:-20.99
PE(LYR):8.24

Loading ...

BioCryst reinstated with a Buy at TD Cowen

TIPRANKS
·
Oct 15, 2025

RBC Capital Reaffirms Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
Oct 15, 2025

BioCryst price target raised to $15 from $14 at Jefferies

TIPRANKS
·
Oct 15, 2025

BioCryst Pharmaceuticals Down Over 10%, on Track for Lowest Close Since June 2024 -- Data Talk

Dow Jones
·
Oct 15, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Reuters
·
Oct 15, 2025

Sector Update: Health Care Stocks Higher Tuesday Afternoon

MT Newswires Live
·
Oct 15, 2025

Hold Rating on BCRX Amid Strategic Acquisition of Astria Therapeutics and Market Challenges

TIPRANKS
·
Oct 15, 2025

BioCryst Pharmaceuticals Shares Down 3%

THOMSON REUTERS
·
Oct 14, 2025

BioCryst Pharmaceuticals Shares Down 9.5% Premarket

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics Shares up 35.7% Premarket on BioCryst's $700 Million Buyout Deal

THOMSON REUTERS
·
Oct 14, 2025

BioCryst to acquire Astria Therapeutics for $13.00 per share

TIPRANKS
·
Oct 14, 2025

BRIEF-BioCryst To Acquire Astria Therapeutics, Strengthening Presence In Hae, Transforming Growth Profile

Reuters
·
Oct 14, 2025

BioCryst Pharmaceuticals to Acquire Astria Therapeutics, Expanding HAE Portfolio and Securing Strategic Financing

Reuters
·
Oct 14, 2025

Astria Therapeutics Inc - BioCryst to Pay $8.55 Cash and 0.59 Shares per Astria Share

THOMSON REUTERS
·
Oct 14, 2025

BioCryst Pharmaceuticals- Deal Valued at $13.00 per Astria Share, $700 Mln Enterprise Value

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics Inc - BioCryst Enters $550 Mln Financing Facility With Blackstone

THOMSON REUTERS
·
Oct 14, 2025

Astria Therapeutics Inc: Expects Cash Portion of Deal Consideration to Be Funded With Cash on Hand & Part of Blackstone Facility

THOMSON REUTERS
·
Oct 14, 2025

RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Oct 09, 2025

RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating

MT Newswires Live
·
Oct 08, 2025

U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals

Reuters
·
Oct 08, 2025